Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.1999
-0.0101 (-4.81%)
At close: Apr 2, 2025, 4:00 PM
0.2098
+0.0099 (4.95%)
After-hours: Apr 2, 2025, 7:00 PM EST
Oragenics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
4.29M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
OGEN News
- 6 days ago - Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress - GlobeNewsWire
- 15 days ago - Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K - GlobeNewsWire
- 27 days ago - Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI) - GlobeNewsWire
- 5 weeks ago - Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment - GlobeNewsWire
- 7 weeks ago - Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment - GlobeNewsWire
- 2 months ago - Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025 - GlobeNewsWire
- 2 months ago - Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO - GlobeNewsWire
- 3 months ago - Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference - GlobeNewsWire